Medicus Pharma Ltd. (MDCX): R&D Expense
$7.72M
Year ended 2025-12-31
$11.89M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.72M | +118.9% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $3.53M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $193.6K | n/a | 2025-03-28, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $7.72M | +118.9% |
| Oragenics Inc (OGEN) | 2025-12-31 | $2.39M | -41.8% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Genprex, Inc. (GNPX) | 2025-12-31 | $9.43M | -10.5% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $5.05M | -59.7% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $453.7K | -95.5% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $4.05M | +12.0% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $7.41M | +64.5% |
Compare MDCX, OGEN, KRSA, GNPX side by side · Screen every company in Pharmaceutical Preparations ↗